Oxford Immunotec
Biotechnology ResearchOxfordshire, United Kingdom201-500 Employees
Oxford Immunotec is now Revvity. For more information on our transformation, please visit: update.oxfordimmunotec.com/transformation
New Product Launches Revvity Inc. has recently launched innovative products like Revvity Transcribe AI and EURORealTime APOE assay, signaling market readiness for cutting-edge solutions in the biotechnology research sector.
Strategic Partnerships Partnerships with companies like BioNano Genomics highlight Revvity's collaborative approach, representing opportunities for joint sales and cross-promotion of complementary products in the genomics and research tool markets.
Investment Inflow With recent investments totaling millions from firms like FORA Capital LLC and Alberta Investment Management Corp, Revvity has the financial backing to expand its sales operations and reach new market segments.
Revenue Growth Potential Revvity's estimated revenue range of $50-100M coupled with consistent funding of $40M indicates a strong financial standing, emphasizing the capacity for investment in sales initiatives to drive growth in market share.
Competitive Landscape Analysis Analyzing Revvity's competitors like Ambry Genetics, Natera, and Guardant Health provides insights into potential customer defection reasons, enabling targeted sales strategies to position Revvity as a preferred choice in the biotechnology research market.
Oxford Immunotec uses 8 technology products and services including Micro Focus, Unpkg, MySQL, and more. Explore Oxford Immunotec's tech stack below.
Oxford Immunotec Email Formats | Percentage |
FLast@oxfordimmunotec.com | 49% |
First_Last@oxfordimmunotec.com | 25% |
First.Last@oxfordimmunotec.com | 16% |
First-Last@oxfordimmunotec.com | 7% |
FirstLast@oxfordimmunotec.com | 1% |
Last@oxfordimmunotec.com | 1% |
First@oxfordimmunotec.com | 1% |
First.Last@revvity.com | 97% |
First.MiddleLast@revvity.com | 1% |
First.Middle@revvity.com | 1% |
Last.First@revvity.com | 1% |
Biotechnology ResearchOxfordshire, United Kingdom201-500 Employees
Oxford Immunotec is now Revvity. For more information on our transformation, please visit: update.oxfordimmunotec.com/transformation
Oxford Immunotec has raised a total of $40M of funding over 8 rounds. Their latest funding round was raised on Oct 04, 2016 in the amount of $40M.
Oxford Immunotec's revenue is in the range of $50M$100M
Oxford Immunotec has raised a total of $40M of funding over 8 rounds. Their latest funding round was raised on Oct 04, 2016 in the amount of $40M.
Oxford Immunotec's revenue is in the range of $50M$100M